{
  "Figure": "nihms808313_page14_343.jpg",
  "Figure_title": "Figure 2. Tumor responses to dabrafenib + trametinib in BRAF V600E–mutant non-small cell  lung cancer Maximum reduction from baseline sum of lesion diameters by best investigator-assessed  confirmed response in ≥ second-line patients (n=57). CR=complete response. NE=not  evaluable. PD=progressive disease. SD=stable disease. "
}